Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

DRUG(2)

MIXED(1)

JDQ443

1 trial

phase_2

maastricht-university-medical-center

Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab

1 trial

phase_2

maastricht-university-medical-center

Trodelvy 200 mg powder for concentrate for solution for infusion

1 trial

phase_2

maastricht-university-medical-center

3 unique interventions2 categories

Analytics

Trial Phases

Phase 22

Trial Status

Recruiting1

Other1

Role Distribution

Principal Investigator2

PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT06401824Phase 2Recruiting

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Brain Metastases, AdultNSCLC Stage IV

PrincipalinvestigatorStart date: 2025-04-24

NCT05999357Phase 2Withdrawn

JDQ443 for KRAS G12C NSCLC Brain Metastases

Brain Metastases, AdultKRAS G12CNon Small Cell Lung Cancer Metastatic

Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Brain Metastases, Adult2 KRAS G12C1 Non Small Cell Lung Cancer Metastatic1 NSCLC Stage IV1 patients with KRAS G12C+ non small cell lung cancer and brain metastases1 Patients with metastatic non-squamous NSCLC pre-treated with platinum-doublet chemotherapy and ICI (for those with targetable oncogenic drivers, pretreated with at least one tyrosine kinase inhibitor and platinum-doublet chemotherapy), and active BM, defined as asymptomatic untreated or unequivocally progressive after local treatment1

Affiliations

Maastricht University Medical Hospital

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mariano Provencio, MD

Fundación GECP President

8 trials

Shared therapeutic areas:

Non Small Cell Lung Cancer MetastaticNSCLC Stage IV

Similarity Score10%

Vincent Lam, MD

Johns Hopkins University

3 trials

Shared therapeutic areas:

NSCLC Stage IV

Similarity Score5%

Fuming Qiu, PhD

Second Affiliated Hospital, Zhejiang University, School of Medicine

3 trials

Shared therapeutic areas:

NSCLC Stage IV

Similarity Score5%

Arielle Elkrief, MD

Centre hospitalier de l'Université de Montréal (CHUM)

3 trials

Shared therapeutic areas:

NSCLC Stage IV

Similarity Score5%

Lien Smets, BA

UZ Leuven

1 trials

Shared therapeutic areas:

Brain Metastases, Adult

Similarity Score5%

Zhengfei Zhu, MD

Fudan University

8 trials

Shared therapeutic areas:

NSCLC Stage IV

Similarity Score5%

Glenn Lesser, MD

Wake Forest University Health Sciences

10 trials

Shared therapeutic areas:

Brain Metastases, Adult

Similarity Score5%

Ali Bekyashev, MD, professor

Blokhin's Russian Cancer Research Center

2 trials

Shared therapeutic areas:

Brain Metastases, Adult

Similarity Score5%

Maryam Rahman, MD

University of Florida

4 trials

Shared therapeutic areas:

Brain Metastases, Adult

Similarity Score5%

Tom Chen, MD, PhD

NeOnc Technologies

2 trials

Shared therapeutic areas:

Brain Metastases, Adult

Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT06401824Phase 2PrincipalInvestigator

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Brain Metastases, AdultNSCLC Stage IV

Recruiting

NCT05999357Phase 2PrincipalInvestigator

JDQ443 for KRAS G12C NSCLC Brain Metastases

Brain Metastases, AdultKRAS G12CNon Small Cell Lung Cancer Metastatic

Withdrawn

All 2 trials loaded